Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17135424 | 99MTC-EDDA/HYNIC-IPSMA AS A RADIOPHARMACEUTICAL FOR DETECTING THE OVEREXPRESSION OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN | December 2020 | October 2022 | Allow | 21 | 2 | 0 | No | No |
| 17132014 | DIAGNOSTIC USAGES OF SHORT-LIVED RADIOPHARMACEUTICALS | December 2020 | November 2022 | Allow | 23 | 1 | 0 | No | No |
| 17131242 | MEDICAL ORGANOGEL PROCESSES AND COMPOSITIONS | December 2020 | October 2023 | Allow | 33 | 3 | 0 | Yes | No |
| 17126282 | GLA DOMAINS AS TARGETING AGENTS | December 2020 | June 2024 | Allow | 42 | 3 | 0 | No | No |
| 17254220 | SOLUTION COMPRISING FLUORESCENT DYE AS FIDUCIAL MARKER | December 2020 | August 2023 | Abandon | 32 | 0 | 1 | No | No |
| 17252036 | EPITHELIALIZING MICROPOROUS BIOMATERIAL FOR USE IN AVASCULAR ENVIRONMENTS AND IN CORNEAL IMPLANTS | December 2020 | November 2024 | Allow | 47 | 2 | 0 | Yes | No |
| 17054087 | PHOTODYNAMIC COMPOSITIONS AND METHODS OF USE | November 2020 | December 2024 | Allow | 50 | 5 | 0 | No | No |
| 17053146 | CYCLODEXTRIN-LINKED POLYVALENT LIGANDS FOR COMPLEXATION OF METAL IONS | November 2020 | March 2023 | Allow | 29 | 2 | 0 | No | No |
| 17051665 | CONTACT LENS INCLUDING NANOPORES | October 2020 | December 2023 | Allow | 37 | 0 | 1 | No | No |
| 17069531 | POROUS NANOCARRIERS FOR THE MONITORING AND TREATMENT OF BLADDER CANCER | October 2020 | April 2023 | Allow | 30 | 2 | 0 | Yes | No |
| 17045029 | COMPOSITIONS FOR RADIOTHERAPY AND USES THEREOF | October 2020 | August 2022 | Abandon | 23 | 0 | 1 | No | No |
| 17029444 | USE OF ENZYME-MODIFIED ISOQUERCITRIN | September 2020 | December 2024 | Allow | 51 | 2 | 2 | Yes | No |
| 17027515 | DEVICES, COMPOSITIONS AND METHODS FOR IMAGING WITH RAMAN SCATTERING AND FOR SUPER-MULTIPLEX VIBRATIONAL IMAGING | September 2020 | September 2024 | Abandon | 48 | 0 | 1 | No | No |
| 16980547 | Ophthalmic Compositions, and Ocular Uses Thereof, of Indigo Carmine | September 2020 | February 2023 | Allow | 29 | 1 | 0 | No | No |
| 16994127 | TOPICAL APPLICATION OF NERVE LABELING DYES FOR IMAGE-GUIDED SURGERY | August 2020 | March 2023 | Allow | 31 | 2 | 0 | Yes | No |
| 16992917 | RADIOPHARMACEUTICAL COMPOSITIONS | August 2020 | February 2023 | Allow | 30 | 2 | 0 | No | No |
| 16935308 | Thermally-Modulated Ultrasound Contrast Agents | July 2020 | October 2023 | Allow | 39 | 3 | 0 | Yes | No |
| 16907779 | IMAGING OF METASTATIC OR RECURRENT CANCER | June 2020 | December 2020 | Allow | 6 | 1 | 0 | Yes | No |
| 16907863 | IMAGING OF METASTATIC OR RECURRENT CANCER | June 2020 | January 2021 | Allow | 6 | 2 | 0 | Yes | No |
| 16769150 | Preparation of Metal-Pyridine Derivative Complexes for Use in Medical Imaging | June 2020 | July 2022 | Allow | 26 | 1 | 0 | No | No |
| 16766206 | Use of mesenchymal lineage precursor cells or stem cells (MLPSCs) for delivery of oligonucleotides in the treatment of cancer | May 2020 | June 2025 | Allow | 60 | 4 | 1 | No | No |
| 16856432 | Diagnosis-treatment Integrated nano-probe for 19F-MR/fluorescence multi-mode molecular imaging and drug-loading and preparation method and application of nano-probe | April 2020 | March 2022 | Allow | 23 | 2 | 0 | Yes | No |
| 16758361 | NOVEL RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | April 2020 | August 2022 | Allow | 28 | 2 | 0 | No | No |
| 16854500 | SYSTEM AND METHOD FOR DIAGNOSIS OF ASTROCYTIC BRAIN TUMOR | April 2020 | August 2021 | Allow | 16 | 1 | 1 | No | No |
| 16840136 | SYSTEMS, COMPOSITIONS, AND METHODS FOR LOCAL IMAGING AND TREATMENT OF PAIN | April 2020 | October 2022 | Abandon | 30 | 1 | 1 | No | No |
| 16839854 | DETECTION OF HIGH RISK DRUSEN | April 2020 | November 2021 | Allow | 20 | 1 | 1 | No | No |
| 16648179 | THE OPTIMAL 225ACTINIUM--213BISMUTH GENERATOR FOR ALPHA-PARTICLE RADIOIMMUNOTHERAPY | March 2020 | March 2022 | Abandon | 24 | 0 | 1 | No | No |
| 16817898 | METHOD OF FREEZE DRYING SURFACTANT-STABILIZED MICROBUBBLES | March 2020 | March 2022 | Allow | 24 | 2 | 1 | No | No |
| 16642185 | ANTI-MESOTHELIN RADIOLABELLED SINGLE DOMAIN ANTIBODIES SUITABLE FOR THE IMAGING AND TREATMENT OF CANCERS | February 2020 | October 2023 | Abandon | 44 | 3 | 0 | Yes | No |
| 16640456 | IN VIVO IMMUNOIMAGING OF INTERFERON-GAMMA | February 2020 | January 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 16779872 | LIPID-ENCAPSULATED GAS MICROSPHERE COMPOSITIONS AND RELATED METHODS | February 2020 | May 2022 | Allow | 27 | 1 | 0 | Yes | No |
| 16778220 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | January 2020 | February 2022 | Allow | 25 | 2 | 0 | No | No |
| 16777025 | DETECTING ARCHITECTURAL REMODELLING IN CELLS, EXTRACELLULAR MATRIX, AND THE TISSUE MICROENVIRONMENT | January 2020 | April 2023 | Abandon | 38 | 0 | 2 | No | No |
| 16628739 | AMPHIPHILIC DYE-COATED INORGANIC NANOPARTICLE CLUSTERS | January 2020 | May 2022 | Allow | 28 | 2 | 1 | No | No |
| 16732618 | GEL FORMULATIONS FOR GUIDING RADIOTHERAPY | January 2020 | November 2023 | Abandon | 47 | 1 | 0 | No | No |
| 16728230 | COMPOSITE EMBOLIZATION BEADS | December 2019 | April 2023 | Allow | 39 | 2 | 0 | No | No |
| 16719615 | LONG-CIRCULATING THERANOSTIC AGENTS FOR DIAGNOSING AND IMAGING METASTATIC TUMORS | December 2019 | October 2023 | Abandon | 46 | 1 | 1 | No | No |
| 16717634 | DEVICES, COMPOSITIONS AND METHODS FOR IMAGING WITH RAMAN SCATTERING | December 2019 | March 2022 | Allow | 27 | 3 | 0 | Yes | No |
| 16623208 | PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY | December 2019 | June 2023 | Allow | 42 | 3 | 0 | No | No |
| 16315643 | METHODS FOR MAKING ULTRASOUND CONTRAST AGENTS | December 2019 | December 2021 | Allow | 35 | 1 | 0 | No | No |
| 16705305 | ULTRAFINE NANOPARTICLES AS MULTIMODAL CONTRAST AGENT | December 2019 | August 2022 | Allow | 32 | 2 | 0 | No | No |
| 16620293 | METHODS FOR LARGE TISSUE LABELING, CLEARING AND IMAGING | December 2019 | May 2025 | Allow | 60 | 3 | 2 | Yes | No |
| 16616368 | ULTRASMALL NANOPARTICLES LABELED WITH ZIRCONIUM-89 AND METHODS THEREOF | November 2019 | September 2022 | Allow | 34 | 2 | 0 | No | No |
| 16687479 | IR DYES FOR FLUORESCENCE IMAGING | November 2019 | July 2022 | Abandon | 31 | 3 | 0 | Yes | No |
| 16687450 | IR DYES FOR FLUORESCENCE IMAGING | November 2019 | August 2021 | Allow | 21 | 1 | 1 | Yes | No |
| 16614286 | Active Pharmaceutical Ingredient Carrier and Production Method of the Same | November 2019 | October 2021 | Allow | 23 | 1 | 0 | No | No |
| 16663190 | METHODS FOR DETERMINING BIODISTRIBUTION OF INTRAVITREAL ADMINISTERED MEDICAMENTS | October 2019 | June 2023 | Allow | 44 | 2 | 0 | Yes | No |
| 16594693 | METHOD AND APPARATUS FOR DETERMINING INTERSTITIAL VOLUME | October 2019 | April 2023 | Abandon | 42 | 1 | 1 | No | No |
| 16592310 | COMPOSITIONS AND METHODS FOR STABILIZING COELENTERAZINE AND ANALOGS AND DERIVATIVES THEREOF | October 2019 | August 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16575056 | LIQUID TOPICAL PHARMACEUTICAL NANO-EMULSION FORMULATIONS | September 2019 | December 2024 | Allow | 60 | 4 | 0 | No | No |
| 16494709 | PIGMENT-COUPLED MANNOSYL SERUM ALBUMIN COMPLEX AND LYMPH NODE-PROBING COMPOSITION COMPRISING SAME | September 2019 | April 2022 | Abandon | 31 | 3 | 0 | No | No |
| 16493613 | METHOD FOR CREATING A RENAL INJURY MODEL TO SCREEN MOLECULES FOR THE TREATMENT OF RENAL INJURY | September 2019 | April 2022 | Allow | 31 | 2 | 1 | No | No |
| 16567731 | DENDRIMER CONJUGATES FOR COATING CELLS | September 2019 | October 2021 | Allow | 25 | 2 | 0 | No | No |
| 16559528 | METHODS AND DEVICES FOR PREPARATION OF ULTRASOUND CONTRAST AGENTS | September 2019 | December 2019 | Allow | 4 | 1 | 0 | Yes | No |
| 16559014 | PSMA inhibitor derivatives for labelling with 99mTc via HYNIC, a radiopharmaceutical kit, radiopharmaceutical preparations and their use in prostate cancer diagnostics | September 2019 | March 2022 | Allow | 31 | 2 | 1 | Yes | No |
| 16489541 | STIMULI-RESPONSIVE PARTICLES ENCAPSULATING A GAS AND METHODS OF USE | August 2019 | June 2021 | Allow | 21 | 1 | 0 | No | No |
| 16552609 | USES OF TRANSDERMAL GLOMERULAR FILTRATION RATE MEASUREMENT IN CONTINUOUS RENAL REPLACEMENT THERAPY | August 2019 | June 2024 | Allow | 58 | 3 | 1 | No | No |
| 16487896 | PROCESS FOR THE PREPARATION OF DOUBLE CROSSLINKED CORE-SHELL POLYMERIC NANOPARTICLES FOR MULTIMODAL IMAGING AND THERANOSTIC APPLICATIONS | August 2019 | January 2022 | Allow | 28 | 3 | 1 | No | No |
| 16486444 | Radiolabeled Pharmaceuticals and Methods of Making and Using Same | August 2019 | July 2022 | Allow | 60 | 2 | 1 | No | No |
| 16485962 | RED FLUORESCENT PROBE FOR USE IN DETECTION OF PEPTIDASE ACTIVITY | August 2019 | October 2023 | Abandon | 50 | 5 | 1 | No | No |
| 16538527 | EARLY DISEASE DETECTION AND THERAPY | August 2019 | April 2022 | Allow | 32 | 2 | 1 | Yes | No |
| 16484312 | USE RADIUM RA-223 DICHLORIDE FOR THE TREATMENT OF MULTIPLE MYELOMA | August 2019 | July 2021 | Abandon | 23 | 1 | 0 | No | No |
| 16532526 | KIT FOR RADIOLABELLING | August 2019 | March 2021 | Allow | 20 | 3 | 0 | Yes | No |
| 16483394 | HYDROPORPHYRINS FOR PHOTOACOUSTIC IMAGING | August 2019 | March 2024 | Allow | 55 | 5 | 0 | No | No |
| 16519834 | STABILIZED NANOBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | July 2019 | December 2020 | Allow | 17 | 1 | 0 | No | No |
| 16479070 | INJECTABLE POLYMER MICRO-DEPOTS FOR CONTROLLED LOCAL DRUG DELIVERY | July 2019 | July 2021 | Abandon | 24 | 1 | 1 | No | No |
| 16478173 | NANOCAPSULES AND METHOD FOR MANUFACTURING THEREOF | July 2019 | April 2022 | Allow | 33 | 3 | 0 | No | No |
| 16512517 | METHOD FOR LABELING RADIOISOTOPE RADIOLABELING COMPOUND AND KIT COMPRISING THE SAME FOR LABELING RADIOISOTOPE | July 2019 | December 2021 | Allow | 29 | 2 | 0 | No | No |
| 16477488 | HIGH-AFFINITY PEPTIDE FOR TUMOR NECROSIS FACTOR ALPHA AND APPLICATION THEREOF | July 2019 | June 2024 | Allow | 60 | 2 | 1 | No | No |
| 16348751 | METHOD OF EVALUATING HEPATIC GLUCOSE UPTAKE CAPACITY | July 2019 | January 2022 | Allow | 32 | 2 | 1 | Yes | No |
| 16472100 | DIAGNOSTIC USAGES OF SHORT-LIVED RADIOPHARMACEUTICALS | June 2019 | November 2021 | Allow | 29 | 2 | 1 | Yes | No |
| 16471678 | TUMOR AND IMMUNE CELL IMAGING BASED ON PD-L1 EXPRESSION | June 2019 | June 2022 | Allow | 36 | 2 | 1 | No | No |
| 16441634 | CHARACTERIZATION OF BIOLOGICAL TISSUES AT A CELLULAR LEVEL USING RED AND FAR-RED FLUORESCENT DYES | June 2019 | November 2020 | Abandon | 17 | 1 | 0 | No | No |
| 16469541 | METHOD FOR LABELING OF SENSITIVE AND THERMOSENSITIVE TARGETING BIOMOLECULES WITH TECHNETIUM BASED COMPOUNDS | June 2019 | June 2021 | Allow | 24 | 2 | 0 | Yes | No |
| 16469581 | NEAR INFRARED (NIR) PHOTODYNAMIC THERAPY (PDT) IN COMBINATION WITH CHEMOTHERAPY | June 2019 | July 2023 | Abandon | 49 | 2 | 0 | No | No |
| 16469037 | LUMINOGENS FOR BIOLOGICAL APPLICATIONS | June 2019 | July 2021 | Allow | 26 | 2 | 1 | Yes | No |
| 16468239 | SCREENING FOR AGENTS THAT TARGET THE ACTIN CYTOSKELETON USING C. ELEGANS EXPOSED TO HEAT SHOCK | June 2019 | December 2020 | Abandon | 18 | 0 | 1 | No | No |
| 16432385 | IOHEXOL POWDER AND METHOD OF USING THE SAME | June 2019 | December 2021 | Allow | 30 | 2 | 1 | No | No |
| 16466222 | MAGNETIC ORGANIC CORE-INORGANIC SHELL MATERIAL, PROCESS FOR PRODUCING SAME AND USES THEREOF FOR THE MAGNETICALLY STIMULATED DELIVERY OF SUBSTANCES OF INTEREST | June 2019 | December 2020 | Abandon | 18 | 1 | 0 | No | No |
| 16501741 | Biodegradable Nanocarrier(s) (BPMOs) for Neutron Capture Therapy and Methods Thereof | May 2019 | September 2021 | Allow | 28 | 3 | 0 | No | No |
| 16463860 | SCAFFOLD-BASED BRACHYTHERAPY WITH INTEGRATED VISUALIZATION | May 2019 | April 2024 | Abandon | 59 | 6 | 0 | No | No |
| 16462098 | NANOCARRIER FOR SELECTIVE FLUORESCENCE LABELING OF CANCER CELL AND PREPARATION METHOD THEREFOR | May 2019 | January 2022 | Allow | 32 | 4 | 0 | No | No |
| 16462090 | EMULSION COMPOSITION FOR CHEMOEMBOLIZATION AND METHOD FOR PRODUCING SAME | May 2019 | August 2022 | Allow | 39 | 3 | 1 | No | No |
| 16412017 | ISOTOPE ENHANCED AMBROXOL FOR LONG LASTING AUTOPHAGY INDUCTION | May 2019 | October 2019 | Allow | 5 | 1 | 0 | Yes | No |
| 16349458 | Imageable Polymers, Methods of Making and Methods of Use Thereof | May 2019 | March 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16409984 | PYRENE-BASED COMPOUNDS FOR INTRACELLULAR ORGANELLE IMAGING APPLICATIONS | May 2019 | January 2022 | Abandon | 32 | 3 | 0 | No | No |
| 16346491 | IDENTIFICATION AND TREATMENT OF TUMORS CHARACTERIZED BY AN OVEREXPRESSION OF THE NEONATAL FC RECEPTOR | April 2019 | June 2022 | Abandon | 37 | 0 | 1 | No | No |
| 16393422 | COMPOSITIONS AND METHODS FOR REDUCING THE RISK OF RADIOCONTRAST-INDUCED NEPHROPATHY | April 2019 | October 2020 | Allow | 18 | 2 | 0 | Yes | No |
| 16393531 | CALCINEURIN INHIBITOR AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG TO REDUCE RISK OF POST-IMAGING PANCREATITIS | April 2019 | July 2021 | Abandon | 27 | 1 | 1 | No | No |
| 16381332 | NANOPARTICLE DIAGNOSTIC AND METHODS FOR TREATING DISEASE | April 2019 | December 2020 | Abandon | 20 | 0 | 1 | No | No |
| 16378792 | MULTIFUNCTIONAL INFRARED-EMITTING COMPOSITES | April 2019 | June 2020 | Allow | 14 | 1 | 0 | No | No |
| 16339446 | CONTRAST MIXTURE AND USE THEREOF | April 2019 | October 2020 | Abandon | 18 | 1 | 0 | Yes | No |
| 16363734 | IMAGE-GUIDED RADIOTHERAPY METHOD FOR TREATING A SUBJECT HAVING A TUMOR | March 2019 | October 2019 | Allow | 6 | 0 | 0 | Yes | No |
| 16295774 | COMPOSITION FOR DETECTING BIOFILMS ON VIABLE TISSUES | March 2019 | June 2021 | Allow | 27 | 4 | 0 | No | No |
| 16291731 | MAGNETIC MICROSTRUCTURES FOR MAGNETIC RESONANCE IMAGING | March 2019 | January 2022 | Allow | 34 | 3 | 1 | No | No |
| 16329661 | TREATMENT OF NON-HODGKIN LYMPHOMA USING LILOTOMAB AND 177LU-LILOTOMAB SATETRAXETAN | February 2019 | July 2021 | Abandon | 29 | 2 | 0 | No | No |
| 16328783 | Methods and Kits for Reducing the Susceptibility of Lipoprotein Particles to Atherogenic Aggregation Induced by Arterial-Wall Enzymes | February 2019 | November 2020 | Abandon | 20 | 1 | 0 | No | No |
| 16328250 | BIFUNCTIONAL ALPHA-SYNUCLEIN BINDING AGENTS AND USES THEREOF | February 2019 | December 2022 | Allow | 46 | 4 | 1 | Yes | No |
| 16327304 | COMPOSITIONS AND METHODS FOR DETECTING CANCER CELLS IN A TISSUE SAMPLE | February 2019 | June 2021 | Abandon | 28 | 2 | 1 | No | No |
| 16280366 | MICROSPHERE AND PREPARATION METHOD THEREOF | February 2019 | August 2021 | Allow | 30 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHIN, JENNIFER L.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHIN, JENNIFER L works in Art Unit 1618 and has examined 577 patent applications in our dataset. With an allowance rate of 48.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner CHIN, JENNIFER L's allowance rate of 48.2% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHIN, JENNIFER L receive 2.62 office actions before reaching final disposition. This places the examiner in the 73% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHIN, JENNIFER L is 40 months. This places the examiner in the 23% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +51.9% benefit to allowance rate for applications examined by CHIN, JENNIFER L. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 17.1% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 28.9% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 15.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 26% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 63.6% of appeals filed. This is in the 43% percentile among all examiners. Of these withdrawals, 57.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 82.1% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.7% of allowed cases (in the 63% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.7% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.